1. Home
  2. IRD vs PYPD Comparison

IRD vs PYPD Comparison

Compare IRD & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IRD
  • PYPD
  • Stock Information
  • Founded
  • IRD 2018
  • PYPD 2008
  • Country
  • IRD United States
  • PYPD Israel
  • Employees
  • IRD N/A
  • PYPD N/A
  • Industry
  • IRD
  • PYPD Medical/Dental Instruments
  • Sector
  • IRD
  • PYPD Health Care
  • Exchange
  • IRD NYSE
  • PYPD Nasdaq
  • Market Cap
  • IRD 36.0M
  • PYPD 29.1M
  • IPO Year
  • IRD N/A
  • PYPD 2020
  • Fundamental
  • Price
  • IRD $1.15
  • PYPD $2.83
  • Analyst Decision
  • IRD Strong Buy
  • PYPD Strong Buy
  • Analyst Count
  • IRD 1
  • PYPD 2
  • Target Price
  • IRD $8.00
  • PYPD $10.50
  • AVG Volume (30 Days)
  • IRD 145.1K
  • PYPD 25.9K
  • Earning Date
  • IRD 02-24-2025
  • PYPD 02-12-2025
  • Dividend Yield
  • IRD N/A
  • PYPD N/A
  • EPS Growth
  • IRD N/A
  • PYPD N/A
  • EPS
  • IRD N/A
  • PYPD N/A
  • Revenue
  • IRD $8,381,000.00
  • PYPD N/A
  • Revenue This Year
  • IRD N/A
  • PYPD N/A
  • Revenue Next Year
  • IRD $29.37
  • PYPD N/A
  • P/E Ratio
  • IRD N/A
  • PYPD N/A
  • Revenue Growth
  • IRD N/A
  • PYPD N/A
  • 52 Week Low
  • IRD $0.81
  • PYPD $2.37
  • 52 Week High
  • IRD $2.71
  • PYPD $6.58
  • Technical
  • Relative Strength Index (RSI)
  • IRD N/A
  • PYPD 43.37
  • Support Level
  • IRD N/A
  • PYPD $2.75
  • Resistance Level
  • IRD N/A
  • PYPD $3.22
  • Average True Range (ATR)
  • IRD 0.00
  • PYPD 0.30
  • MACD
  • IRD 0.00
  • PYPD -0.02
  • Stochastic Oscillator
  • IRD 0.00
  • PYPD 11.17

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

About PYPD PolyPid Ltd.

PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.

Share on Social Networks: